Zobrazeno 1 - 10 of 35 pro vyhledávání: '"Femke H M Prince"'
1
Akademický článek
Prevalence and predictors for sustained remission in rheumatoid arthritis.
Autor: Yoon-Kyoung Sung, Kazuki Yoshida, Femke H M Prince, Michelle L Frits, Soo-Kyung Cho, Jung-Yoon Choe, Hye-Soon Lee, Jisoo Lee, Shin-Seok Lee, Dae-Hyun Yoo, Simon M Helfgott, Nancy A Shadick, Michael E Weinblatt, Daniel H Solomon, Sang-Cheol Bae
Publikováno v: PLoS ONE, Vol 14, Iss 4, p e0214981 (2019)
ObjectiveRemission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching remission. U
Externí odkaz: https://doaj.org/article/4eeb01db7e2c49c59eaa562fa546b04d
Zobrazit plný text záznamu
3
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis
Autor: Faekah Gohar, Marion A J van Rossum, Janneke Anink, Gerd Horneff, Dirk Holzinger, Koert M. Dolman, Esther P A H Hoppenreijs, Michael Frosch, Lisette W A van Suijlekom-Smit, Simona Ursu, Lucy R. Wedderburn, Rebecca ten Cate, Halima Moncrieffe, Dirk Foell, Femke H M Prince
Publikováno v: The Journal of Rheumatology, 45, 547-554
Journal of Rheumatology, 45(4), 547-554. Journal of Rheumatology
Journal of Rheumatology, 45(4), 547-554
Journal of rheumatology, 45(4), 547-554. Journal of Rheumatology
Journal of Rheumatology
The Journal of Rheumatology, 45, 4, pp. 547-554
Objective.Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line methotrexate (MTX) or anti-tumor necrosis factor (TNF) therapy, with even fewer achieving ≥ American College of Rheumatology Pediatric 70%
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6a0e4d660f01ee6d619bcec11db85f
https://doi.org/10.3899/jrheum.170438
Zobrazit plný text záznamu
5
TNF-alpha inhibitors for juvenile idiopathic arthritis
Autor: Anna K. Dorai Raj, Femke H M Prince, Johannes C. van der Wouden, Kathleen Tymms, Lisette W A van Suijlekom-Smit, Peter P. M. Cheung, Marieke H Otten
Publikováno v: Cochrane Database of Systematic Reviews, 2018(8):Cd008598. John Wiley & Sons Ltd.
Cochrane Database Systematics Review, 7, 1-10. John Wiley & Sons Ltd.
Cochrane Database of Systematic Reviews, 2018(8):CD008598. John Wiley and Sons Ltd
Prince, F H M, Dorai Raj, A K, Otten, M H, Cheung, P P M, Tymms, K E, van Suijlekom-Smit, L W A & van der Wouden, J C 2018, ' TNF-alpha inhibitors for juvenile idiopathic arthritis ', Cochrane Database of Systematic Reviews, vol. 2018, no. 8, CD008598 . https://doi.org/10.1002/14651858.CD008598.pub2
Cochrane database of systematic reviews (Online), 2018(8):CD008598. John Wiley and Sons Ltd
The Cochrane Library
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The aim of this review is to assess the benefit and safety of TNF-α inhibitors in JIA.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26cc7e1f247e5e20a3260ba434d7aaa3
https://doi.org/10.1002/14651858.cd008598.pub2
Zobrazit plný text záznamu
6
Prevalence and predictors for sustained remission in rheumatoid arthritis
Autor: Jung Yoon Choe, Nancy A. Shadick, Shin-Seok Lee, Michael E. Weinblatt, Kazuki Yoshida, Michelle L. Frits, Soo Kyung Cho, Yoon Kyoung Sung, Femke H M Prince, Simon M. Helfgott, Daniel H. Solomon, Jisoo Lee, Dae Hyun Yoo, Sang Cheol Bae, Hye Soon Lee
Publikováno v: PLoS ONE, Vol 14, Iss 4, p e0214981 (2019)
PLoS One (online), 14(4):e0214981. Public Library of Science
PLoS ONE
textabstractObjective Remission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::999f99f855f8c897566fb3f1392d30b6
https://doi.org/10.1371/journal.pone.0214981
Zobrazit plný text záznamu
7
Cost of Biologics in the Treatment of Juvenile Idiopathic Arthritis: A Factor not to be Overlooked
Autor: Lisette W A van Suijlekom-Smit, Femke H M Prince
Publikováno v: Pediatric Drugs. 15:271-280
Biologics are a promising treatment option for juvenile idiopathic arthritis (JIA) but drug costs are very high compared to conventional treatment. From a socioeconomic view the additional costs of new interventions should be weighed against their in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d5ac5942ded3e4ac49c6bd093644ef5
https://doi.org/10.1007/s40272-013-0023-7
Zobrazit plný text záznamu
8
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register
Autor: Esther P A H Hoppenreijs, Wineke Armbrust, Femke H M Prince, Lisette W A van Suijlekom-Smit, Rebecca ten Cate, Marion A J van Rossum, Marieke H Otten, Y. Koopman-Keemink, J. Merlijn van den Berg, Joost F Swart, Philomine A van Pelt, Simone L Gorter, Nico M Wulffraat, Koert M. Dolman, Sylvia Kamphuis, Janneke Anink
Publikováno v: Rheumatology, 52(4), 712-717
Rheumatology, 52, 4, pp. 712-7
Rheumatology, 52, 712-7
Rheumatology, 52(4), 712-717. Oxford University Press
Rheumatology, 52, 712-717. Oxford University Press
Rheumatology (Oxford, England), 52(4), 712-717. Oxford University Press
Item does not contain fulltext Objective. Because TNF inhibitors are not approved for persistent oligoarticular JIA (oJIA), although they are used off-label, we evaluated their effectiveness in patients in this category. Methods. Persistent oJIA pati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a44584333b0ab828af22a4ae0008fb6
https://doi.org/10.1093/rheumatology/kes373
Zobrazit plný text záznamu
9
Performance of Matrix-Based Risk Models for Rapid Radiographic Progression in a Cohort of Patients With Established Rheumatoid Arthritis
Autor: Espen A Haavardsholm, Christine Iannaccone, Michelle L. Frits, Nina P. Paynter, Femke H M Prince, Michael E. Weinblatt, Siri Lillegraven, Tore K Kvien, Nancy A. Shadick, Daniel H. Solomon
Publikováno v: Arthritis Care & Research. 65:526-533
Rheumatoid arthritis (RA) is a chronic disease that can cause severe joint damage and disability. During the last decades, the number of therapeutic agents and the knowledge about treatment strategies for RA have increased substantially (1). This has
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3eb2359c4bd5f4fff2c3d4352cdad5
https://doi.org/10.1002/acr.21870
Zobrazit plný text záznamu
10
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
Autor: Rebecca ten Cate, Simone L Gorter, Wijnand A. A. Swen, Joost F Swart, Janneke Anink, Marion A J van Rossum, Nico M Wulffraat, Lisette W A van Suijlekom-Smit, Koert M. Dolman, Philomine A van Pelt, Danielle M.C. Brinkman, J. Merlijn van den Berg, Marieke H Otten, Sylvia Kamphuis, Wineke Armbrust, Y. Koopman-Keemink, Femke H M Prince, Esther P A H Hoppenreijs
Publikováno v: Rheumatology, 52, 9, pp. 1674-9
Rheumatology, 52(9), 1674-1679
Rheumatology, 52, 1674-9
Rheumatology, 52(9), 1674-1679. Oxford University Press
Rheumatology (Oxford, England), 52(9), 1674-1679. Oxford University Press
Item does not contain fulltext Objectives. To evaluate differences in baseline characteristics between etanercept- and adalimumab-treated JIA patients and to reveal factors that influence the choice between these TNF inhibitors, which are considered
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021b81569ca5acd0d2b40b5c86f33055
https://doi.org/10.1093/rheumatology/ket170
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje